ClinicalTrials.gg
CompletedNCT00430248CONFIRMSUpdated Feb 2, 2012Results posted

Efficacy and Safety of Oral Febuxostat in Participants With Gout

A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed at 258 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,269
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
Largest of 29
2,269 · median 109
Started
2007
the only one that year
Phase 3
10 of 29
none open now
Registered
6th of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one has the largest enrollment, is the only one that started in 2007, is one of 10 in phase 3, and was the 6th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.

Read the detailed description

Renal impairment is common in subjects with gout, with the prevalence ranging from 50% to 70%. This population represents an unmet medical need as uricosuric drugs are contraindicated in these patients, and the only available treatment, allopurinol, may have to be dose reduced to avoid overt side effects.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.

Treatment duration will be 6 months.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • tophi
  • hyperuricemia
  • uric acid
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has one or more of the American Rheumatism Association criteria for the diagnosis of gout.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL).

Exclusion criteria

Exclusion Criteria:

  • Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study.
  • Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation.
  • History of xanthinuria.
  • Alcohol consumption greater than 14/week.
  • History of significant concomitant illness.
  • Active liver or peptic ulcer disease.
  • Has rheumatoid arthritis requiring treatment.
  • Has estimated less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight.
  • Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,269 participants (actual)

Study arms

  • Experimental
    Febuxostat 40 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 80 mg QD

    Drug: Febuxostat

  • Active comparator
    Allopurinol 200 mg or 300 mg QD

    (dependent on renal function)

    Drug: Allopurinol

Interventions

  • Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.

    Also known as: TMX-67, Tei-6720, Uloric

  • Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months. Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily.

    Also known as: Zyloprim

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.

    The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.

    Time frame: Last Visit on treatment (up to 6 months)

Secondary outcomes

  1. Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl

    The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

    Time frame: Last Visit on treatment (up to 6 months)

  2. Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.

    Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 2 visit was summarized.

    Time frame: Month 2

  3. Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.

    Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 4 visit was summarized.

    Time frame: Month 4

  4. Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.

    Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.

    Time frame: Month 6

  5. Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.

    Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 2 visit was summarized.

    Time frame: Month 2

  6. Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.

    Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 4 visit was summarized.

    Time frame: Month 4

  7. Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.

    Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 6 visit was summarized.

    Time frame: Month 6

  8. Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.

    The percentage of subjects whose serum urate level was \<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

    Time frame: Last Visit on treatment (up to 6 months)

  9. Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit

    Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 2 visit was summarized.

    Time frame: Month 2

  10. Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit

    Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 4 visit was summarized.

    Time frame: Month 4

  11. Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit

    Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 6 visit was summarized.

    Time frame: Month 6

  12. Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit

    The percentage of subjects whose serum urate level was \<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

    Time frame: Last Visit on treatment (up to 6 months)

  13. Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.

    Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.

    Time frame: Baseline and Month 2

  14. Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit

    Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.

    Time frame: Baseline and Month 4

  15. Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.

    Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.

    Time frame: Baseline and Month 6

  16. Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.

    The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

    Time frame: Baseline and Last Visit on treatment (up to 6 months)

07

Results

Posted Jul 16, 2009

Participant flow

Subjects were enrolled at 324 sites in the United States from 16 February 2007 to 12 March 2008.

Participant flow — Overall Study
MilestoneFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Started757756756
Completed632598621
Not completed125158135
Withdrew: Adverse event496164
Withdrew: Protocol violation1024
Withdrew: Personal reasons12249
Withdrew: Lost to follow-up283328
Withdrew: Therapeutic failure111
Withdrew: Withdrawal by subject142016
Withdrew: Inclusion/exclusion criteria not met020
Withdrew: Gout flare372
Withdrew: Reason not specified8811

Outcome measures

PrimaryPercentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.

The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.

Time frame:
Last Visit on treatment (up to 6 months)
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.45.267.142.1
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Difference in percentage: 3.1 · 95% CI -1.9 to 8.1
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.233 (The test for superiority was performed using Fisher's exact test (two-tailed 0.05 significance level).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (Comparisons between treatment groups were performed using Fisher's exact test (two-tailed 0.05 significance level).) · Difference in percentage: 24.9 · 95% CI 20.1 to 29.8
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (Comparisons between treatment groups were performed using Fisher's exact test (two-tailed 0.05 significance level).) · Difference in percentage: 21.9 · 95% CI 17.0 to 26.8
SecondaryPercentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl

The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame:
Last Visit on treatment (up to 6 months)
Reported as:
Number · percentage of subjects
Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl49.771.642.3
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.021 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 2 visit was summarized.

Time frame:
Month 2
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.49.174.143.2
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.031 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 4 visit was summarized.

Time frame:
Month 4
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.47.175.245.5
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.578 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.
percentage of participantsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.48.975.346.6
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.426 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 2 visit was summarized.

Time frame:
Month 2
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.15.445.911.7
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.050 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 4 visit was summarized.

Time frame:
Month 4
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.15.051.613.5
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.428 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<5.0 mg/dL at the Month 6 visit was summarized.

Time frame:
Month 6
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.19.349.714.8
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.041 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.

The percentage of subjects whose serum urate level was \<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

Time frame:
Last Visit on treatment (up to 6 months)
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.16.544.013.2
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.083 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit

Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 2 visit was summarized.

Time frame:
Month 2
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit2.117.51.5
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.421 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 4 visit was summarized.

Time frame:
Month 4
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit2.018.61.4
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.520 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<4.0 mg/dL at the Month 6 visit was summarized.

Time frame:
Month 6
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit3.120.31.8
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.195 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryPercentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit

The percentage of subjects whose serum urate level was \<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.

Time frame:
Last Visit on treatment (up to 6 months)
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit2.517.51.5
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = 0.196 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · Fisher Exact · p = <0.001 (The a priori threshold for statistical significance was 0.05 (two-tailed).)
SecondaryMean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.

Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.

Time frame:
Baseline and Month 2
Reported as:
Mean · percent change from baseline
Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.-35.1 ± 12.8-44.5 ± 15.5-33.8 ± 13.2
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = 0.079 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
SecondaryMean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit

Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.

Time frame:
Baseline and Month 4
Reported as:
Mean · percent change from baseline
Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit-34.9 ± 13.1-45.5 ± 15.6-34.5 ± 12.8
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = 0.685 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
SecondaryMean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.

Time frame:
Baseline and Month 6
Reported as:
Mean · percent change from baseline
Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.-35.6 ± 13.2-45.1 ± 16.0-34.4 ± 13.3
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = 0.153 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
SecondaryMean Percent Change From Baseline in Serum Urate Levels at Final Visit.

The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame:
Baseline and Last Visit on treatment (up to 6 months)
Reported as:
Mean · percent change from baseline
Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.-33.1 ± 15.5-40.6 ± 19.9-31.3 ± 16.2
Statistical analysis
  • Febuxostat 40 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = 0.050 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 80 mg QD vs Allopurinol 200 mg or 300 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)
  • Febuxostat 40 mg QD vs Febuxostat 80 mg QD · ANOVA · p = <0.001 (P-value is from contrast within the framework of the ANOVA with significance at the 0.05 level.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 40 mg QD———
Febuxostat 80 mg QD———
Allopurinol 200 mg or 300 mg QD———
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Cholecystitis and CholelithiasisHepatobiliary disorders0/7570/7563/756
Lower Respiratory Tract and Lung InfectionsInfections and infestations1/7571/7563/756
Prostatic Neoplasms MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7571/7563/756
Disturbances in Consciousness NECNervous system disorders0/7570/7563/756
Cardiac Conduction DisordersCardiac disorders0/7572/7560/756
Coronary Artery Disorders NECCardiac disorders2/7570/7562/756
Ischaemic Coronary Artery DisordersCardiac disorders1/7572/7561/756
Pain and Discomfort NECGeneral disorders1/7572/7561/756
Bacterial Infections NECInfections and infestations1/7571/7562/756
Non-Site Specific Injuries NECInjury, poisoning and procedural complications0/7572/7560/756
Most frequent other events
Most frequent other events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QD
Upper Respiratory Tract InfectionsInfections and infestations71/75753/75657/756
Liver Function AnalysesInvestigations63/75752/75650/756
Diarrhoea (Excluding Infective)Gastrointestinal disorders45/75747/75657/756
Musculoskeletal and Connective Tissues Signs and Symptoms NECMusculoskeletal and connective tissue disorders43/75738/75632/756

Baseline characteristics

Age, Customized
Age, Customized(subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
<45 years of age192196180568
45 to <65 years of age4504324451327
≥65 years of age115128131374
Age Continuous
Age Continuous(years)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
Mean52.5 ± 11.6853.0 ± 11.7952.9 ± 11.7352.8 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
Female354647128
Male7227107092141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
Hispanic or Latino474953149
Not Hispanic or Latino7107077022119
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
American Indian or Alaska Native610622
Asian26253788
Native Hawaiian or Other Pacific Islander11101132
Black or African American837867228
White6206186251863
More than one race1115834
Unknown or Not Reported0022
Body Mass Index
Body Mass Index(subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
<18.5 kilograms per meter² (kg/m²)0112
18.5 kg/m² to <25 kg/m²504642138
25 kg/m² to <30 kg/m²215232236683
≥30 kg/m²4904764761442
Missing2114
Cardiovascular Disease
Cardiovascular Disease(subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
No336316320972
Yes4214404361297
Renal Function
Renal Function(subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDAllopurinol 200 mg or 300 mg QDTotal
Moderate Renal Impairment130136136402
Mild Renal Impairment3493673651081
Normal Renal Function278253255786

2 further baseline measures are reported on the registry.

08

Study locations

258 sites
  • Birmingham, Alabama, United States
  • Hoover, Alabama, United States
  • Hueytown, Alabama, United States
  • Huntsville, Alabama, United States
  • Mobile, Alabama, United States
  • Montgomery, Alabama, United States
  • Northport, Alabama, United States
  • Ozark, Alabama, United States
  • Tuscaloosa, Alabama, United States
  • Chandler, Arizona, United States
  • Gilbert, Arizona, United States
  • Mesa, Arizona, United States
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Sierra Vista, Arizona, United States
  • Tucson, Arizona, United States
  • Fort Smith, Arkansas, United States
  • Jonesboro, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Carmichael, California, United States
  • Clovis, California, United States
  • Concord, California, United States
  • El Centro, California, United States
  • Fair Oaks, California, United States
  • Fullerton, California, United States
  • Huntington Beach, California, United States
  • Irvine, California, United States
  • Laguna Hills, California, United States
  • LaJolla, California, United States
  • Los Angeles, California, United States
  • Pasadena, California, United States
  • Rancho Cucamonga, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Luis Obispo, California, United States
  • Santa Barbara, California, United States
  • Santa Maria, California, United States
  • Torrance, California, United States
  • Tustin, California, United States
  • Vallejo, California, United States
  • Vista, California, United States
  • Walnut Creek, California, United States
  • West Covina, California, United States
  • Westlake Village, California, United States
  • Whittier, California, United States
  • Boulder, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Highlands Ranch, Colorado, United States
  • Littleton, Colorado, United States
  • Longmont, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Danbury, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Washington, District of Columbia, United States
  • Aventura, Florida, United States
  • Boynton Beach, Florida, United States
  • Brandon, Florida, United States
  • Daytona Beach, Florida, United States
  • DeLand, Florida, United States
  • Delray Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Gainsville, Florida, United States
  • Hallandale, Florida, United States
  • Hialeah, Florida, United States
  • Holly Hill, Florida, United States
  • Jupiter, Florida, United States
  • Kissimmee, Florida, United States
  • Largo, Florida, United States
  • Miami, Florida, United States
  • Naples, Florida, United States
  • New Port Richey, Florida, United States
  • New Smyrna Beach, Florida, United States
  • Opa Locka, Florida, United States
  • Orlando, Florida, United States
  • South Miami, Florida, United States
  • St. Petersburg, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Winter Haven, Florida, United States
  • Zephyrhills, Florida, United States
  • Atlanta, Georgia, United States
  • Conyers, Georgia, United States
  • Decatur, Georgia, United States
  • Dunwoody, Georgia, United States
  • Gainesville, Georgia, United States
  • Marietta, Georgia, United States
  • Stockbridge, Georgia, United States
  • Honolulu, Hawaii, United States
  • Boise, Idaho, United States
  • Coeur d'Alene, Idaho, United States
  • Meridian, Idaho, United States
  • Nampa, Idaho, United States
  • Arlington Heights, Illinois, United States
  • Chicago, Illinois, United States

Showing the first 100 of 258 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6. PubMed 20370912 ↗
  • Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008. PubMed 21353107 ↗
  • Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715. PubMed 22132950 ↗
  • Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680. PubMed 22052584 ↗
  • Becker MA, MacDonald PA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12. PubMed 23683134 ↗
  • Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of age. BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11. PubMed 22436129 ↗
  • Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012 Feb 9;13:15. doi: 10.1186/1471-2474-13-15. PubMed 22316106 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Feb 1, 2007
Start
Feb 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Jul 16, 2009
Last update
Feb 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00430248
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 1, 2007
Start date
Feb 2007
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jul 16, 2009
Last update
Feb 2, 2012

Study contacts

Medical Director
study chair · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion